High-flow nasal oxygen versus conventional oxygen therapy in patients with COVID-19 pneumonia and mild hypoxaemia: a randomised controlled trial

Crimi, Claudia; Noto, Alberto; Madotto, Fabiana; Ippolito, Mariachiara; Nolasco, Santi; Campisi, Raffaele; De Vuono, Stefano; Fiorentino, Giuseppe; Pantazopoulos, Ioannis; Chalkias, Athanasios; Libra, Alessandro; Mattei, Alessio; Scala, Raffaele; Clini, Enrico; ERGAN, BEGÜM; Lujan, Manel; Winck, Joao; Giarratano, Antonino; Carlucci, Annalisa; Gregoretti, Cesare; Groff, Paolo; Cortegiani, Andrea

doi:10.1136/thoraxjnl-2022-218806

High-flow nasal oxygen versus conventional oxygen therapy in patients with COVID-19 pneumonia and mild hypoxaemia: a randomised controlled trial

Atıf İçin Kopyala

Crimi C., Noto A., Madotto F., Ippolito M., Nolasco S., Campisi R., ...Daha Fazla

THORAX, sa.4, ss.354-361, 2023 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Basım Tarihi: 2023
Doi Numarası: 10.1136/thoraxjnl-2022-218806
Dergi Adı: THORAX
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
Sayfa Sayıları: ss.354-361
Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Rationale In patients with COVID-19 pneumonia and mild hypoxaemia, the clinical benefit of high-flow nasal oxygen (HFNO) remains unclear. We aimed to examine whether HFNO compared with conventional oxygen therapy (COT) could prevent escalation of respiratory support in this patient population.